Trenzyme Licenses SEFEX Cell Line Technology from Celonic AG
News Oct 09, 2015
Trenzyme GmbH and Basel based Celonic AG have announced the closure of a license agreement on Celonics CHO-K1 based cell line expression platform SEFEX. Under the terms of the deal, Trenzyme acquires the non-exclusive rights and know-how on this technology to establish high performance cell lines for R&D and GMP production purposes for its clients.
The SErum Free EXpression technology, SEFEX, is a royalty-free cell line based on CHO-K1 cells. This powerful platform offered by the Swiss CDMO Celonic can be used throughout the entire development ranging from laboratory cultures to production scale.
It is robust, highly performant, easy to implement and guarantees maximum productivity, substantial cost savings and scale-up stability for more project safety. As an experienced R&D cell line developer, Trenzyme is looking forward to enter a new market by the closure of the licence agreement on Celonics SEFEX technology.
"We are very happy since the deal enables us to extend our cell line services. From now on, we can additionally offer the generation of a cell line which can not only be used for R&D but also for subsequent GMP manufacturing purposes" said Reinhold Horlacher, founder and CEO of Trenzyme. "With this agreement, we can save our clients time and money on their way from research to pharmaceutical production. There is no further need of two different cell lines as the generated R&D cell line can be directly upgraded to GMP manufacturing. In addition, we can provide maximal comparability of their drug substances from R&D to clinical research. All that at a very competitive price."
"Just last year, we obtained titers beyond 7 g/L of an antibody product, so the technology proved to be extremely efficient. This means less Cost of Goods for the clients." said Karlheinz Landauer, Chief Operating Officer of Celonic. "As Celonics partner, Trenzyme has received a technical service package and was verified by our quality management. Hence, we can guarantee its clients to take over their approved R&D cell lines and upgrade them to a fully GMP compliant Master Cell Bank. In addition, we can transfer the cell lines seamlessly to our process development and GMP manufacturing units."
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE
Researchers Discover Key Link Between Mitochondria and Cocaine AddictionNews
Researchers were able to block response in mitochondria to cocaine.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018